These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 23458591)
21. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082 [TBL] [Abstract][Full Text] [Related]
22. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883 [TBL] [Abstract][Full Text] [Related]
23. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Gross E; Rothstein M; Dombek S; Juknis HI Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962 [TBL] [Abstract][Full Text] [Related]
24. Effects of eplerenone versus losartan in patients with low-renin hypertension. Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319 [TBL] [Abstract][Full Text] [Related]
25. Hypertension, angiotensin II, aldosterone, and race. Ben-Yehuda O J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216 [No Abstract] [Full Text] [Related]
26. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576 [TBL] [Abstract][Full Text] [Related]
28. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study. Shavit L; Neykin D; Lifschitz M; Slotki I Clin Nephrol; 2011 Nov; 76(5):388-95. PubMed ID: 22000559 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension. Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561 [TBL] [Abstract][Full Text] [Related]
30. Eplerenone: a review of its use in essential hypertension. Croom KF; Perry CM Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538 [TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. Li JS; Flynn JT; Portman R; Davis I; Ogawa M; Shi H; Pressler ML J Pediatr; 2010 Aug; 157(2):282-7. PubMed ID: 20400095 [TBL] [Abstract][Full Text] [Related]
32. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue? Manolis AA; Manolis TA; Melita H; Manolis AS Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898 [TBL] [Abstract][Full Text] [Related]
34. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Moore TD; Nawarskas JJ; Anderson JR Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934 [TBL] [Abstract][Full Text] [Related]
35. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826 [TBL] [Abstract][Full Text] [Related]